The first-in-class Preservation
& Protection Solutions (PPS),
engineered to protect organs from Ischemia-Reperfusion-Injury
Protect the graft when it matters most and build the foundation for lasting transplantation success
Perla® is CE-Marked
Organs need more than storage, they need protection.
Standard cold storage solutions keep organs cold and static but fail to protect them against ischemia‑reperfusion injury (IRI). IRI is unavoidable in kidney and liver transplantation and is a leading cause of primary non‑function, delayed graft function, early allograft dysfunction, and acute and chronic rejection.
A critical step in transplantation
Despite major advances in our understanding of IRI, preservation solutions have barely evolved in over 30 years, leaving organs inadequately protected. Yet preservation is the first and most critical step in transplantation, strongly shaping early graft performance and long‑term outcomes. Today’s transplantation landscape, shaped by increasing complexity and challenges, demands more than just cold storage; it requires active biochemical protection.
Protection when it matters most.
With this imperative in mind, ALS developed Perla®, a first‑in‑class “Prime Guard Solution”. Perla® is the first Preservation & Protection Solution (PPS) engineered to deliver immediate, frontline defense against ischemia‑reperfusion injury (IRI).
A breakthrough composition
Perla® combines three well‑established pharmacologic agents, trimetazidine, carvedilol, and tacrolimus, each showing activity in protecting cells against ischemia–reperfusion injury (IRI). Perla® unique formulation targets the key biological drivers of IRI, preserving cellular integrity and metabolic reserves at the moment the graft is most vulnerable.
These ancillary substances are within a PEG‑ and Sodium‑rich extracellular solution that does not induce red blood cell aggregation or vasoconstriction, thereby supporting optimal microcirculation during preservation. Perla® enhances organ protection and functional recovery by combining effective washout with targeted IRI‑protective agents.
Beyond cold storage solutions
Perla®’s high performance has been demonstrated in ex vivo models of both non‑steatotic and steatotic livers, where it preserved cellular function, limited cell death, and enhanced graft function and survival. Preclinical studies are ongoing to further validate Perla®’s performance in protecting organs from IRI, in kidney and liver transplantation models.
By design, Perla® goes beyond just maintaining an organ’s condition. It protects the graft’s molecular defense systems to withstand the of reperfusion, laying the foundation for successful transplantation.
You wish to discover Perla® in detail ?
You are a healthcare professional and would like to know more.
We are at your disposal to meet you and explain our innovation in detail.
